It has been revealed that BRCA1 germline mutation, and HER2 and ER expressions were candidate tumour biomarkers for the risk of breast or ovarian cancer, and for therapeutic assessment of breast and gastric cancers, respectively. This evidence concerns the gene BRCA1 and neoplasm.